Orchid Pharma Limited announced a critical update regarding its pending Scheme of Amalgamation with Dhanuka Laboratories Limited. The order concerning the merger petition, which involves both companies and their respective shareholders and creditors, has been reserved for formal pronouncement by the Hon’ble National Company Law Tribunal (NCLT) on March 18, 2026. The company confirmed it will notify the Stock Exchanges immediately upon receiving the official NCLT order copy.
Key Update on Merger Scheme
Orchid Pharma Limited issued an important disclosure on March 18, 2026, concerning the proposed Scheme of Amalgamation (the “Scheme”). This Scheme involves the amalgamation of Dhanuka Laboratories Limited (the “Amalgamating Company”) with Orchid Pharma Limited (the “Amalgamated Company”).
NCLT Status Update
In continuation of prior disclosures regarding the merger petition pending before the Hon’ble National Company Law Tribunal (“NCLT”), the company informed the exchanges that the final order regarding the Scheme—affecting both companies, their shareholders, and creditors—has been reserved for formal pronouncement today, March 18, 2026.
Next Steps and Disclosure Timeline
Orchid Pharma Limited confirmed that it will proceed to notify both the National Stock Exchange of India Limited and BSE Limited immediately upon receipt of the formal copy of the Hon’ble NCLT order. Furthermore, the complete information will be made available on the Company’s official website following the receipt of the order.
The intimation was signed by Manish Dhanuka, Managing Director of Orchid Pharma Limited.
Source: BSE
